RecruitingPhase 3NCT03150693
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Sponsor: Alliance for Clinical Trials in Oncology
Aurora, CO · Boulder, CO · +452 more sites
Leukemia clinical trials in Aurora, CO
17 recruiting leukemia studies with a site in Aurora, CO.
RecruitingPhase 2NCT06317662
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Sponsor: National Cancer Institute (NCI)
Aurora, CO · +114 more sites
RecruitingPhase 3NCT07007312
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Sponsor: Kura Oncology, Inc.
Aurora, CO · Denver, CO · +42 more sites
RecruitingPhase 1 / Phase 2NCT04065399
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Sponsor: Syndax Pharmaceuticals
Aurora, CO · +21 more sites
RecruitingPhase 3NCT07277231
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Sponsor: BeOne Medicines
Aurora, CO · +21 more sites
RecruitingPhase 3NCT06852222
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Sponsor: Janssen Research & Development, LLC
Aurora, CO · +58 more sites
RecruitingPhase 3NCT04293562
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Sponsor: Children's Oncology Group
Aurora, CO · Denver, CO · +184 more sites
RecruitingPhase 1NCT04972942
Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma
Sponsor: New York Medical College
Aurora, CO · +15 more sites
RecruitingPhase 1NCT07347418
CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML
Sponsor: University of Colorado, Denver
Aurora, CO
RecruitingPhase 1 / Phase 2NCT04726241
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Sponsor: PedAL BCU, LLC
Aurora, CO · Denver, CO · +162 more sites
RecruitingPhase 1NCT06247787
A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
Sponsor: Children's Oncology Group
Aurora, CO · +18 more sites
RecruitingPhase not listedNCT05978141
A Registry for People With T-cell Lymphoma
Sponsor: Memorial Sloan Kettering Cancer Center
Aurora, CO · +25 more sites
RecruitingPhase 2NCT06588478
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Sponsor: Loxo Oncology, Inc.
Aurora, CO · +20 more sites
RecruitingPhase 3NCT06428019
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Sponsor: AbbVie
Aurora, CO · +31 more sites
RecruitingPhase 1NCT05292664
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Sponsor: Andrew E. Place, MD
Aurora, CO · +4 more sites
RecruitingPhase 1NCT06429449
Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
Sponsor: University of Colorado, Denver
Aurora, CO
RecruitingPhase 1 / Phase 2NCT04150497
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Sponsor: Cellectis S.A.
Aurora, CO · Denver, CO · +12 more sites
Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.